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Abstract
Background
Sight loss from trachoma is the end result of a scarring disease process starting in early
childhood and characterised by repeated episodes of conjunctival inflammation (active tra-
choma). Subsequently, the conjunctiva becomes scarred, causing the eyelashes to turn
inwards and scratch the cornea (trichiasis), damaging the corneal surface and leading to
corneal opacification and visual impairment. It is thought that this process is initiated and
driven by repeated infection with Chlamydia trachomatis. We review published longitudinal
studies to re-examine the disease process, its progression rates and risk factors.
Methodology/Principal Findings
We searched PubMed for studies presenting incidence and progression data for the differ-
ent stages of trachoma natural history. We only included studies reporting longitudinal data
and identified 11 publications meeting this criterion. The studies were very heterogeneous
in design, disease stage, duration, size and location, precluding meta-analysis. Severe con-
junctival inflammation was consistently associated with incident and progressive scarring in
five studies in which this was examined. One study reported an association between C. tra-
chomatis infection and incident scarring. No studies have yet demonstrated an association
between C. trachomatis infection and progressive scarring. Several studies conducted in
regions with low prevalence active disease and C. trachomatis infection found evidence of
on-going scarring progression.
Conclusions/Significance
Overall, there are few longitudinal studies that provide estimates of progression rates and
risk factors, reflecting the challenges of conducting such studies. Our understanding of this
disease process and the long-term impact of control measures is partial. Intense conjuncti-
val inflammation was consistently associated with scarring, however, direct evidence dem-
onstrating an association between C. trachomatis and progression is limited. This suggests
that on-going chlamydial reinfection may not be mandatory for progression of established
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scarring, indicating that sight threatening trichiasis may continue to evolve in older people in
formerly endemic populations, that will require service provision for years after active dis-
ease is controlled.
Introduction
Sight loss from trachoma is the end result of a scarring disease process. The widely accepted
view is that it follows the natural history illustrated in Fig 1 [1]. Trachoma is caused by the obli-
gate intracellular bacterium Chlamydia trachomatis. In a typical endemic setting, repeated
chlamydial infection of the conjunctiva starts early in life. This can initiate recurrent episodes
of chronic conjunctival inflammation, characterised by the formation of lymphoid follicles
most easily seen in the upper tarsal conjunctival surface. In the Simplified WHO grading sys-
tem this is referred to as Trachoma Inflammation—Follicular (TF), which is equivalent to F2
and F3 of the detailed WHO-FPC grading system [2, 3]. In some cases the inflammation can
be more marked, with severe papillary hypertrophy, referred to as Trachoma Inflammation—
Intense (TI) in the simplified system and P3 in the detailed system [2, 3]. These signs of “Active
Trachoma”, TF and TI, are most frequently found in younger children, becoming less prevalent
with increasing age. They are characterised by a cell-mediated adaptive immune response to C.
Fig 1. Natural history of trachoma: Normal healthy tarsal conjunctiva without inflammation, follicular
trachoma (TF), intense inflammatory trachoma (TI), scarring trachoma (TS), trichiasis (TT) and
corneal opacification (CO).Ct: Chlamydia trachomatis.
doi:10.1371/journal.pntd.0004859.g001
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trachomatis [4]. With time trachomatous conjunctival scarring (TS) gradually develops as a
result of inflammation-induced tissue damage [2, 4]. The Simplified WHO grading of TS is
taken to be equivalent to the grades C1-C3 of the Detailed WHO grading system [2, 3]. In
highly endemic regions TS can develop in childhood, whereas in less endemic regions it usually
becomes visible from early adulthood.
Chronic conjunctival inflammation is also frequently found in adults with established con-
junctival scarring, Fig 1. This later stage conjunctival inflammation is usually not follicular in
nature, C. trachomatis infection is rarely detected and it is characterised by a prominent innate
epithelial immune response [4–6]. It is possible that non-chlamydial infections, dryness and
irritation of the scarred conjunctiva also contribute to driving inflammation and progression in
the context of established scarring, Fig 1 [4].
Eventually the conjunctival scarring causes the eyelashes to turn in, such that they now
scratch the surface of the eye, which is referred to as trachomatous trichiasis (TT) [2]. If the tri-
chiasis is left uncorrected it traumatises the surface of the cornea resulting in sight loss from
corneal opacification (CO). Again other pathogens (bacteria and fungi) may contribute to the
development of corneal scarring through secondary infections, Fig 1.
The most recent World Health Organization (WHO) estimates suggest that about 232 mil-
lion people live in trachoma endemic areas in 51 countries [7]. Approximately 1.2 million peo-
ple are irreversibly blind from trachoma. A further 40 million are thought to be affected by
active trachoma, and are at risk of developing scarring and blindness [8]. To meet this large
public health challenge, the WHO-led Global Alliance for the Elimination of Trachoma by
2020 recommends the implementation of the SAFE strategy which tackles the disease at differ-
ent stages: Surgery to correct trichiasis, Antibiotics to treat chlamydial infection and Facial
cleanliness and Environmental improvements to suppress transmission of infection [1].
Despite many years of research, there are relatively few detailed longitudinal studies that
investigate the rates and determinants of disease progression through these stages. An under-
standing of this process is relevant to disease control measures and planning. In this review we
draw together and re-examine the literature on the natural history of trachoma, to identify the
rates and risk factors for progression through the stages of this disease process.
Methods
References were identified through searches of PubMed for articles published at any date, by
use of the terms (i) “trachoma” AND (ii) “scarring”, “trichiasis”, “cornea opacity”, “Chlamydia
trachomatis”, “visual impairment” OR “blindness”. Articles resulting from these searches and
relevant publications cited in these articles were reviewed. We included longitudinal studies
which: (1) reported the incidence and/or progression of conjunctival scarring; (2) the incidence
and/or progression of trachomatous trichiasis; (3) the incidence and/or progression of corneal
opacification; (4) the incidence and/or progression of visual impairment and blindness from
trachoma. For the purposes of this review, we define incident disease (conjunctival scarring, tri-
chiasis or corneal opacification) to be the development of these signs in individuals who did
not previously have evidence of them. We reviewed the bibliographies of publications meeting
these inclusion criteria for any additional publications that might also meet them. This search
yielded 1595 articles and one author screened the titles and abstracts of these for potentially eli-
gible publications. Two authors (AR and MB) jointly reviewed potential articles for eligibility
and extracted the data.
For each disease progression stage we extracted and recorded core information using a stan-
dardised form and present this in the Tables. The core information included country, year of
publication, population active disease level, study design, study population, duration of follow-
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up, numbers of participants, number and proportion progressing, grading system, use of anti-
biotic for infection control. Additional information on specific associations with disease pro-
gression and clinical inflammation, C. trachomatis infection, gender and age were collected if
reported. For the purpose of this review the prevalence levels of TF in the populations or
regions studied were categorised as follows: Hypoendemic<10%, Mesoendemic 10–20% and
Hyperendemic>20% [9]. For some reports data on active disease prevalence was not pre-
sented, therefore, we have categorised the active disease prevalence level for such studies based
on other contemporary sources of information about disease prevalence for the same regions.
Clinical signs are reported using the specific trachoma grading systems used in the study
(details provided in Tables 1–5), these were usually either the Simplified or the Detailed WHO
Trachoma Grading Systems [2, 3]. Due to the heterogeneity of the study designs and reports a
meta-analysis was not performed.
Results/Discussion
Progression from Active to Scarring Trachoma
We identified four prospective cohort studies that reported the relationship between active tra-
choma and the subsequent development of incident scarring (new conjunctival scarring in
those with no prior visible conjunctival scarring), Table 1 [10–13]. Three of these were from
Tanzania and one from Tunisia. In addition, we identified a report of a mathematical model of
the five year incidence of TS, based on cross-sectional age-stratified data from Tanzania [14].
The study designs were heterogeneous in terms of sample size, clinical grading system used,
MDA treatment background and study duration. All four were conducted in hyperendemic
communities, which had not previously received mass drug administration (MDA) for tra-
choma control. After enrolment all the communities received some form of antibiotic treat-
ment, although this was variable in nature and frequency (Table 1). The duration of the follow-
up varied from 5 to 14 years. The assessment of clinical signs used either the simplified or
detailed WHO Trachoma Grading Systems [2, 3]. In two studies the development of incident
scarring was identified by a change in the clinical field grading [10, 11]. In the other two studies
the development of incident scarring was identified through the grading of photographs, using
a more detailed scar grading system [12, 13].
The earliest study, from Tunisia, found that 17% of individuals (n = 82, children and young
adults) without conjunctival scarring at baseline developed severe scarring with distortion of
the tarsal plate (C3) over a 14 year period (Table 1) [10]. This study also reported on scarring
progression and incident TT, which are discussed below. It did not report the proportion of
individuals who developed milder degrees of scarring during the same period, nor did it report
chlamydial infection data. A strong association was found between the presence of TI at base-
line and the subsequent development of severe scarring (RR = 18), and a weaker association for
the presence of TF (RR = 2.8). Unfortunately, the reported details are fairly limited, and the
scarring incidence rates are not disaggregated by gender.
The first Tanzanian study was a 7-year cohort of children (baseline age 1–7 years) with and
without “constant severe trachoma” (defined by the presence of TI on at least 3 out of 4 exami-
nations during the baseline year) [11]. At 7 years, 29.2% of children with “constant severe tra-
choma” (n = 96) developed incident TS, compared to only 9.6% of the comparison group
(n = 94). Incident scarring was independently associated with “constant severe trachoma”,
increasing age and female gender. Incident scarring was associated with the presence of TI at
the 7-year time-point. The cohort was tested for C. trachomatis infection at the 7-year time-
point only; those that had incident scarring were more likely to be infected at that point (OR
2.48, p = 0.02).
Rates and Risk Factors for Blinding Trachoma
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Table 1. Progression from active to scarring trachoma.
Country /
Year
Study design Participants Progression to TS Comments
Tunisia,
1990 [10]
Prospective 14-year study of the resident
population of a trachoma-endemic
Tunisian village. Conducted to identify
clinical signs and environmental factors
associated with development of scarring.
A random sample of people seen at
baseline were re-examined at 14-years.
Baseline, 1969–72: 2000 people, of
all ages. Follow-up, 1986–87: 213
people who were aged 1 month to 32
years at baseline. Loss to follow-up:
Information not provided. Baseline
Scarring:
• C0 82 (38.7%)
• C1 51 (24.0%)
• C2 58 (27.4%)
• C3 21 (9.9%)
• Baseline: 82 had no
scarring (C0).
• At 14 years 14/82
(17.1%) had developed
severe scarring (C3)
• Incident TS rate: 1.2%/
year
• Hyperendemic setting (Regional
survey data)
• No previous MDA, however during the
1980’s systematic antibiotic treatment
was carried out which dramatically
reduced active trachoma.[35]
• Clinical grading: detailed WHO-FPC
system.[3]
• The data presentation and analysis in
this report are relatively limited.
However, it represents the ﬁrst long term
study of the relationship between
inﬂammation and subsequent scarring.
The report only includes the rate of
transition from no scarring (C0) to C3
(the most severe grade with distortion),
it is likely that many other individuals
without scarring at baseline would have
gone on to develop some lesser degree
of scarring (C1 or C2). Data not
disaggregated by gender.
• Predictors of severe scarring (C3) at
14 years (whole group of 213):
 Baseline TF (F2/F3): RR 2.8
 Baseline TI (P3): RR 18
 Household density (closeness of
houses): RR 1.3
Tanzania,
1997 [14]
Mathematical model of the 5-year
incidence of TS in women. Using age-
stratiﬁed cross-sectional data on the
different clinical stages.
• 4898 women in survey.
• Loss to follow-up: N/A
• Incident TS (model) by
age group: 15–19 years:
3.1% / 5 yrs; 55–59 age:
14.3% / 5 yrs
• Incident TS rate: 15–19
years: 0.6%/year; 55–59
years: 4.9%/year
• Hyperendemic setting
• No previous MDA.
• Clinical grading: simpliﬁed WHO
system.[2]
Tanzania,
2001 [11]
Prospective cohort study of “constant
severe trachoma” in the development of
incident trachoma scarring in children.
Cases of “constant severe trachoma”
were deﬁned by the presence of severe
inﬂammatory trachoma (TI) on at least 3
out of 4 examinations during the baseline
year. The comparison group was deﬁned
as children “without constant severe
trachoma” (up to 2 episodes of TI out of
4). The two groups were matched by
age, gender and neighbourhood. Swabs
were collected for C. trachomatis
infection by PCR at 7 years only.
• Baseline, 1989: Age 1–7 years;
Cases 118; Comparison 118.
• Follow-up, 1996: Age 8–14 years;
Cases 96; Comparison 94
• Loss to follow-up: 42
• 7 year Incident TS:
Cases: 28/96 (29.2%);
Comparison 9/94 (9.6%).
• Incident TS rate: Cases:
4.2%/year; Comparison:
1.4%/year
• Hyperendemic setting. (Regional
survey data)
• No previous MDA. After baseline MDA
with topical tetracycline eye ointment
was administered for 30 days.[36]
• Clinical grading: simpliﬁed WHO
system.[2]
• Predictors of incident scarring at 7
years:
 Age (per year): OR 1.32, 95% CI 1.07–
1.62
 Female: OR 2.49, 95% CI 1.02–6.08
 Constant severe trachoma: OR 4.85,
95% CI 2.05–11.4
• Incident scarring was highest in those
who had TI and lowest in those that had
TF at the 7-year follow-up (1996):
 Cases: TF 1/30 (3.3%), TI 22/40
(55.0%), None 5/26 (19.2%)
 Comparison: TF 1/30 (3.3%), TI 5/13
(38.5%), None 3/51 (5.9%)
• C. trachomatis infection at the 7-year
time point was more frequently detected
in individuals that developed scarring:
TS 12/26 (42.9%) vs no TS 20/67
(29.9%), OR 2.48, p = 0.02. The clinical /
infection status of individuals from the
two groups was unknown during the 7
year interval.
(Continued)
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In a separate cohort of Tanzanian children (n = 183) who were aged<10 years at baseline,
the 5-year cumulative incidence of TS was 17.4%. In a logistic regression model, the develop-
ment of TS was strongly associated with increasing age, female gender, “constant severe tra-
choma” (10+ follicles or TI or both, on at least 3 of 5 visits during the initial 18 months) and/or
“constant C. trachomatis infection” (infection on at least 3 of 5 visits during the initial 18
months), compared to those without constant severe trachoma or constant infection, Table 1
[12]. The infection and disease states were not analysed as separate variables.
In the fourth prospective study to investigate incident conjunctival scarring in previously
unaffected individuals, a cohort of Tanzanians of all ages (n = 367) was recruited and followed
for 5 years (Table 1) [13]. The overall cumulative incidence of TS was 20.4% in 5 years. The
Table 1. (Continued)
Country /
Year
Study design Participants Progression to TS Comments
Tanzania,
2009 [12]
Prospective cohort study of the impact of
C. trachomatis infection and severe
trachoma on development of scarring.
Participants were all children under 10
years (at baseline) living in a single
village; examined at baseline, 2, 6, 12,
18 months and 5 years. Deﬁnitions:
• “Constant infection”: infection on at
least 3 of 5 visits during the initial 18
months.
• “Constant severe trachoma”: severe
trachoma (10+ follicles or TI or both) on
at least 3 of 5 visits during the initial 18
months.
• “Constant infection and constant
severe trachoma”: combination of the
above.
• Cohort of 189 children, aged 0–9
years at baseline (2000).
• Loss to follow-up: 6
• Baseline TS prevalence:
6/189 (3.0%)
• Incident TS by 5 years:
32/183 (17.4%)
• Incident TS rate: 3.5%/
year
• Hyperendemic setting (70% TF at
baseline)
• Clinical grading: simpliﬁed WHO
system with additional more detailed
grading of scarring on photographs.[2,
13]
• MDA was administered at baseline and
at 18 months.
• Chlamydia test: Amplicor PCR, Roche
• Baseline:
 Scarring: male; 2/90 (2.1%), female; 4/
99 (4.0%)
 C. trachomatis infection: male; 35/90
(38.8%), female 43/99 (43.4%)
• Incident TS at 5 years by disease/
infection group:
 No infection/disease: 4/59 (6.8%)
 Sporadic infection/disease: 12/79
(15.2%)
 Constant severe trachoma only: 7/20
(35.0%)
 Constant infection only: 4/9 (44.4%)
 Constant severe trachoma and
constant infection: 5/16 (31.2%)
• Signiﬁcant predictors of incident
scarring at 5 years (multivariable logistic
regression model):
 Age (per year) OR 1.26, 95% CI 1.08–
1.47
 Gender (female) OR 2.55, 95% CI
1.13–5.75
 Sporadic infection/disease (relative to
no infection/disease): OR 1.76, 95% CI
0.48–6.50
 Constant infection and/or severe
disease (relative to no infection/
disease): OR 5.74, 95% CI 2.39–13.77
Tanzania,
2009 [13]
Prospective cohort study of incident and
progressive scarring. Participants were
individuals of all ages, examined at
baseline and 5-years.
• Baseline (2000): 990 people of all
ages.
• Follow-up (2005): 487 people of
which 453 had gradable images from
all time points.
• Loss to follow-up: 437
• Baseline TS prevalence:
86/453 (18.9%)
• Incident TS by 5 years:
75/367 (20.4%)
• Incident TS rate: 4.1%/
year
•Hyperendemic setting (70% TF at
baseline)
• Clinical grading: simpliﬁed WHO
system with additional more detailed
grading of scarring on photographs.[2,
13]
• MDA was administered at baseline and
at 18 months.
• There was a trend of increasing
incidence with age, p = 0.038
doi:10.1371/journal.pntd.0004859.t001
Rates and Risk Factors for Blinding Trachoma
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Table 2. Progression of scarring trachoma.
Country /
Year
Study design Participants Progression of TS to TS+ Comments
Tunisia,
1990 [10]
Prospective 14-year study of the
resident population of a trachoma-
endemic Tunisian village. Conducted
to identify clinical signs and
environmental factors associated
with development of scarring. A
random sample of people seen at
baseline were re-examined at
14-years.
Baseline, 1969–72: 2000 people of
all ages. Follow-up, 1986–87: 213
people who were aged 1 month to
32 years at baseline. Loss to follow-
up: Information not provided.
Baseline Scarring:• C0 82 (38.7%)
• C1 51 (24.0%)
• C2 58 (27.4%)
• C3 21 (9.9%)
Progressive Scarring, by 14
years: “worse scarring”
reported in 146/213
(68.5%):• C0 to C3: 14/82
(17.1%)
• C1 to C3: 10/51 (19.2%)
• C2 to C3: 40/58 (69.0%)
Progressive TS rate:
• C0 to C3: 1.2%/year
• C1 to C3: 1.4%/year
• C2 to C3: 4.9%/year
• Hyperendemic setting (Regional
survey data)
• No previous MDA, however during
the 1980’s systematic antibiotic
treatment was carried out which
dramatically reduced active
trachoma.[35]
• Clinical grading: detailed WHO-FPC
system.[3]
• The data presentation and analysis
in this report are relatively limited.
The “worse scarring” analysis
appears to include incident scarring
cases as well as deterioration of
established scarring. Not possible to
sub-divide the presented data. Data
not disaggregated by gender.
• Predictors of severe scarring (C3) at
14 years (whole group of 213):
 Baseline TF (F2/F3): RR 2.8
 Baseline TI (P3): RR 18
 Household density (closeness of
houses): RR 1.3
Tanzania,
2009 [13]
Prospective cohort study of incident
and progressive scarring.
Participants were people of all ages,
examined at baseline and 5-years.
• Baseline, 2000: 990 people of all
ages.
• Follow-up, 2005: 487 people of
which 453 had gradable images
from all time points.
• Loss to follow-up: 437
• Baseline TS prevalence:
86/453 (18.9%).
• Progressive TS by 5
years: 40/85 (47.1%)
• Progressive TS rate:
9.4%/year
• Hyperendemic setting (70% TF at
baseline)
• Clinical grading: simpliﬁed WHO
system with additional more detailed
grading of scarring on photographs.
[2]
• MDA was administered at baseline
and at 18 months.
• There was no evidence for a
difference in the proportion showing
progression with age
Ethiopia,
2015 [17]
Prospective cohort study of
progressive scarring in adults with
established scarring and minor
trichiasis (<6 lashes touching the
eye). Examined and swabs collected
every 6 months for two years. Swabs
were analysed for C. trachomatis
infection and expression of several
genes potentially involved with
inﬂammation and scarring.
Progressive scarring was determined
by direct comparison of baseline and
two year photographs.
• Baseline, 2008: 650 participants.
• 585 people had paired
photographs from baseline and 24
months.
• Loss to follow-up: 65
• Progressive scarring by 2
years:
• 135/585 (23.1%)
• Progressive TS rate:
11.6%/year.
• Hyperendemic setting (Regional
survey data)
• Clinical grading: detailed WHO-FPC
system, with more detailed grading of
scarring on photographs.[3]
• MDA had been delivered in this
region of Ethiopia several times
before the start of the study and
during the two year period.
• Progressive scarring was strongly
associated with and increasing
number of inﬂammatory (P2/P3)
episodes: OR 5.93, 95%CI 3.3–10.6,
p<0.0001.
• There was no association between
scarring progression and age,
gender or body mass index. No
episode of C. trachomatis infection
were detected.
• Gene expression analysis (106
progressors vs 106 non-
progressors): clinical inﬂammation
(not scarring progression) was
associated with increased
expression of S100A7, IL1B, IL17A,
CXCL5, CTGF, CEACAM5,MMP7,
CD83 and reduced SPARCL1.
(Continued)
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cumulative incidence of scarring generally increased with age, although it was noted it was par-
ticularly rapid in younger children, for reasons that could not be determined. In this study the
relationship between incident TS and the signs of active trachoma or the presence of infection
were not reported. The study found that at baseline and at five years, across all age groups, the
cross-sectional prevalence of TS was higher in females than males. However, data disaggregated
by gender were not presented on the 5-year incidence of new scarring in this cohort.
The data from a mathematical model supports these longitudinal studies. The 5-year cumu-
lative incidence of new scarring in females, based on cross-sectional data, indicated increasing
incidence with increasing age: 3.1% in 15–19 year olds and 14.3% in 55–59 year olds [14].
Overall, there are surprisingly few prospective studies and relatively limited data investigat-
ing the link between active trachoma and/or chlamydial infection and the development of inci-
dent TS. Three studies present consistent evidence that severe conjunctival inflammation (TI)
is associated with substantially increased risk of new scarring several years later [10–12]. The
evidence from these studies for an association between TF, in the absence of TI, and the devel-
opment of scarring is less clear. In the Tunisian study there was an increase in risk associated
with TF (RR = 2.8), however, no test statistics (95%CI) were provided to assess the strength of
this evidence [10]. In the Tanzanian populations TF was common and affected most of the
children at some point in the observation periods [11, 12]. However, those that were found to
have only sporadic disease or infection were not at a significantly higher risk of incident TS
than those with no episodes of disease or infection [12].
The evidence from these prospective studies demonstrating a link between repeated or per-
sistent C. trachomatis infection and subsequent incident TS is limited to only one study from
Table 2. (Continued)
Country /
Year
Study design Participants Progression of TS to TS+ Comments
Tanzania,
2015 [17]
Prospective cohort study of
progressive scarring in adults with
established scarring. Examined and
swabs collected every 6 months for
two years. Swabs were analysed for
C. trachomatis infection and
expression of several genes
potentially involved with inﬂammation
and scarring. Progressive scarring
was determined by direct
comparison of baseline and two year
photographs.
• Baseline, 2009: 804 participants
• 577 people had paired
photographs from baseline and 24
months
• Progressive scarring by 2
years:
• 173/577 (30.0%)
• Progressive TS rate:
15.0%/year.
• Hypoendemic setting (Regional
survey data)
• Clinical grading: detailed WHO-FPC
system, with more detailed grading of
scarring on photographs.[3]
• No MDA has been delivered to this
region.
• Progressive scarring was strongly
associated with and increasing
number of inﬂammatory (P2/P3)
episodes: OR 5.76, 95% CI 2.6–12.7,
p<0.0001.
• No association between scarring
progression and gender or body
mass index.
• Progressors were a bit older: 50.9
years vs 43.8 years, p<0.0001. C.
trachomatis infection was very rare
and not associated with progression.
• Gene expression analysis (97
progressors vs 97 non-progressors):
clinical inﬂammation (not progressive
scarring) was associated with
increased expression of S100A7,
IL17A, CXCL5,MMP7 and
CEACAM5. Only IL1B (Fold Change
1.54, p = 0.0067) and S100A7 (Fold
Change 1.43, p = 0.027) had
associations with progressive
scarring of marginal signiﬁcance.
doi:10.1371/journal.pntd.0004859.t002
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Table 3. Progression to trachomatous trichiasis.
Country /
Year
Study design Participants Progression of TS to TT Comments
Tunisia,
1990 [10]
Prospective 14-year study of the
resident population of a trachoma-
endemic Tunisian village.
Conducted to identify clinical signs
and environmental factors
associated with development of
scarring. A random sample of
people seen at baseline were re-
examined at 14-years.
Baseline, 1969–72: 2000 people
of all ages. Follow-up, 1986–87:
213 people who were aged 1
month to 32 years at baseline.
Loss to follow-up: Information not
provided. Baseline Scarring:
• C0 82 (38.7%)
• C1 51 (24.0%)
• C2 58 (27.4%)
• C3 21 (9.9%)
Progression to TT occurred in
17/213 (8.0%). The risk of
progression to TT was related
to the baseline scarring
severity:
• C0 1/82 (1.2%)
• C1 0/51 (0%)
• C2 8/58 (13.8%)
• C3 8/21 (38.1%)
Progression from TS to TT:
0.6%/year
• C0: 0.1%/year
• C1: 0.0%/year
• C2: 1.1%/year
• C3: 2.7%/year
• Hyperendemic setting (Regional
survey data)
• No previous MDA, however
1980s systematic antibiotic
treatment was carried out which
dramatically reduced active
trachoma[35]
• Clinical grading: detailed
WHO-FPC system.[3]
• The data presentation and
analysis in this report are relatively
limited. The risk of developing TT
was greater with increasing
baseline scarring and
inﬂammation.
Tanzania,
1997 [14]
Mathematical model of the 5 year
incidence of TT in women. Using
age-stratiﬁed cross-sectional data
on the different clinical stages.
• 4898 women in survey.
• Loss to follow-up: N/A
• Incidence of TT by age in all
women: 15–19 age 0.3% / 5
years 55–59 age 6.4% / 5
years
• Incidence of TT by age in
women with TS at baseline:
15–19 age 3.2% / 5 years;
55–59 age 15.1% / 5 years
• Incident TT rate in all
women: 15–19 years: 0.06%/
year; 55–59 years: 1.3%/
year.
• Incident TT rate in women
with TS: 15–19 years: 0.6%/
year; 55–59 years: 3.0%/year
• Hyperendemic setting
• No previous MDA.
• Clinical grading: simpliﬁedWHO
system.[2]
Tanzania,
1999 [19]
Prospective 7 year cohort study to
measure the incidence of TT in
women with and without baseline
conjunctival scarring. The cohort
was recruited from six villages. All
women were examined for TS and
TT at baseline (1989). Seven years
later all available women who had
TS (without TT) at baseline and a
similar sized random sample of
those without any TS were re-
examined.
• Cohort participants who
completed the follow-up at 7
years: 523 with TS at baseline.
503 without TS at baseline.
• Loss to follow-up: 468
• Incidence of trichiasis at
7-years by baseline TS
status: TS: 9.2% / 7 years No
TS: 0.6% / 7 years.
• Incident TT rate: 1.3%/year
in women with pre-existing
scarring. 0.1%/year with no
TS
• Hyperendemic setting (Regional
survey data)
• No previous MDA
• Clinical grading: simpliﬁedWHO
system.[2]
• Predictors of trichiasis:
 Age (increase per year): OR
1.03, 95%CI: 1.01–1.06
 Infection at follow up: OR 2.51,
95%CI: 1.1–5.69
Gambia,
2001 [20]
The 1986 Gambian National
Blindness and Eye Disease Survey
was a 1% sample of the total
population. In this 8174 people
were examined. 12 years later
individuals who were found to have
TS in 1986 were retraced and
assessed for the development of TT
and CO.
• Baseline, 1986: 639/8174 people
18 years were found to have TS
• Follow-up, 1998: 326/639 (51%)
were re-examined
• Loss to follow-up: 313
• Progressed from scarring to
trichiasis: 19/297, 6.4% / 12
years.
• Incident TT rate in people
with TS: 0.5%/year
• Hypoendemic setting (Regional
survey data)
• No previous MDA
• Clinical grading: simpliﬁedWHO
system.[2]
• Risk factor for trichiasis:
Old age: OR 1.07, 95% CI 1.01–
1.12
Gambia,
2010 [21]
Five year prospective study of the
population of 14 adjacent Gambian
villages.
• Baseline, 2001: 592 people >15
years
• 5-years, 2006: 456 people >15
years
• Loss to follow-up: 136
• Baseline TT: 9/592 (1.5%).
• 5-year TT: 6/456 (1.3%)
• Incident TT Cases: 2/456,
0.4% / 5 years
• Incident TT rate in all adults:
0.1%/year
• Mesoendemic setting (15% TF at
baseline)
• No previous MDA
• Clinical grading: detailed
WHO-FPC system.[3]
• At 5-years, 3/6 case had TT at
baseline and 1/6 was a new
resident
doi:10.1371/journal.pntd.0004859.t003
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Tanzania [12]. In this study, data on disease and infection were combined for the analysis, so it
is not possible to determine the independence of the effect of infection from disease. Notably,
although a small proportion of individuals with only sporadic disease and/or infection did
develop TS, they were not at significantly greater risk of scarring than individuals who had no
disease or infection episodes documented. This might suggest that in a programmatic context,
reducing the pressure of infection and associated TI through MDAmight reduce disease in the
majority of individuals below a threshold required for the development of scarring.
As would be expected from the known cross-sectional age-specific prevalence of TS from
population based surveys, the three prospective Tanzanian studies and the mathematical
model found clear and consistent evidence of increasing risk of incident TS with increasing age
[11–14]. However, it is noteworthy that some incident scarring was developing during child-
hood in these populations. Similarly, the prospective Tanzanian studies found that females
were at consistently higher risk of incident TS than males, probably because of a greater life-
time exposure to chlamydial infection [11–13].
West and colleagues suggested that there might be two distinct routes to the development of
TS [11]. Firstly, in the “classical”model, which may account for the majority of TS cases, are
individuals who are repeatedly exposed to C. trachomatis. In this group the risk of TS is pri-
marily determined by the cumulative number of infection episodes experienced. This is
Table 4. Progression of trachomatous trichiasis.
Country /
Year
Study design Participants Progression of TT to TT+ Comments
Gambia,
2002 [22]
One year longitudinal study of
individuals with TT in at least one
eye.
• Baseline, 1996: 190 people.
• Major trichiasis 135; Minor
trichiasis 55.
• Follow-up, 1997: 169 people
were re-examined at 12
months.
• Loss to follow-up: 21
• Progression of Minor to Major
trichiasis: 18/55 (33%) / 1 year
• Progression of unilateral to
bilateral TT: 21/46 (46%) / 1
year
• Hypoendemic setting (Regional
survey data)
• No previous MDA.
• Clinical grading: simpliﬁedWHO
system.[2]
Gambia,
2006 [23]
Four year longitudinal study of
individuals with TT in at least one
eye, who had declined surgery.
Examined at baseline and 4 years.
• Baseline, 1996: 220 people
• Follow-up, 2000: 153 people
were re-examined
• Loss to follow-up: 67
• Progression of Minor to Major
trichiasis: 28/75 (37.3%) eyes.
• Progression Rate: 9.3%/year
• Progression of unilateral to
bilateral trichiasis: 12/42 (29%)
eyes
• Progression rate: 7.3%/yr
• Hypoendemic setting (Regional
survey data)
• No previous MDA
• Clinical grading: detailed WHO-FPC
system.[3]
• Univariate association between TT
progression and conjunctival
inﬂammation (P2 or P3) at 4-years:
OR 3.07, 95%CI 1.23–7.70, p =
0.017. This was not signiﬁcant in a
logistic regression model.
• C. trachomatis was detected in 2/
146 (1.4%) tested at 4-years and was
not associated with TT progression.
Ethiopia
2011 [24,
25]
Two year prospective randomised
controlled trial of epilation vs
surgery for Minor trichiasis (<6
lashes). 650 individuals were
randomised to the epilation arm at
baseline and followed every six
months for two years. Outcome
measure was presence of 5
+ lashes. At two years all were
offered TT surgery, 383 chose to
continue epilating and were
followed up for an additional two
years.
• Baseline, 2008: 650 people
• Primary outcome data
available for 637 people at 2
years (2010).
• Follow-up, 2012: 383 people
who continued epilating were
re-examined. Loss to follow-
up: at 2 years: 13; at 4 years:
267
• At 2 years: progression of
Minor to Major trichiasis: 84/637
(13.2%) eyes.
• Progression rate: 6.6% / year.
• At 4 years, comparing
baseline to four years, 82 /383
(21.4%) had more eyelashes
touching and 200/383 (52.2%)
had fewer.
• Hyperendemic setting (Regional
survey data)
• Clinical grading: detailed WHO-FPC
system, with more detailed grading of
scarring on photographs.[3]
• MDA had been delivered in this
region of Ethiopia several times
before the start of the study and
during the two year period.
doi:10.1371/journal.pntd.0004859.t004
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Table 5. Progression to corneal opacification, visual impairment and blindness.
Country /
Year
Study design Participants Progression of TT to CO Comments
Tanzania,
1997 [14]
Mathematical model of the 10 year
incidence of CO in women. Using age-
stratiﬁed cross-sectional data on the
different clinical stages.
• 4898 women in survey.
• Loss to follow-up: N/A
Incidence of CO,
attributable to trachoma:
All women:
• 15–24 yrs 0.16% / 10
years
• 45–54 yrs 2.80% / 10
years
Progression rate:
• 15–24 yrs 0.02%/year
• 45–54 yrs 0.3%/year
Women with TT:
• 15–24 yrs 27.2% / 10
years
• 45–54 yrs 53.5% / 10
years
Progression rate:
• 15–24 yrs 2.72%/year
• 45–54 yrs 5.35%/year
• Hyperendemic setting
• No previous MDA
• Clinical grading: simpliﬁed WHO system.[2]
• In this model around half of all corneal
opacity was due to causes other than
trachoma. In women under 35 years these
other causes dominated. In older ages
trachoma was the main cause.
Gambia,
2001 [20]
The 1986 Gambian National Blindness and
Eye Disease Survey was a 1% sample of
the total population. In this 8174 people
were examined. 12 years later the people
who were found to have TS in 1986 were
retraced to assess them for the
development of TT and CO.
• Baseline, 1986: 639/8174
people 18 years were found
to have TS
• Follow-up, 1998: 326/639
(51%) were re-examined
• Loss to follow-up: 313
• Progressed from TS to
CO: 18/302 (5.9%) / 12
years.
• Progression rate: 0.5%/
year
• Progressed from TT to
CO: 4/20 (20%) / 12 years.
• Progression rate: 1.7%/
year
• Hypoendemic setting (Regional survey
data)
• No previous MDA
• Clinical grading: simpliﬁed WHO system.[2]
• Risk factor for corneal opacity:
 Trichiasis at baseline: OR 8.4, 95% CI 1.8–
39.2
• Old age: OR 1.07, 95% CI 1.01–1.12
• Progressed from TS to incident visual
impairment / blindness:
 53/321 (16.5%), all causes
 8/321 (2.5%), attributed to cornea scarring
• Progressed from TT to incident visual
impairment / blindness:
 4/26 (15.4%), all causes
 2/26 (7.7%), attributed to cornea scarring
Gambia,
2002 [22]
One year longitudinal study of individuals
with TT in at least one eye. Progression was
considered signiﬁcant if the baseline cornea
grading had been CC0 / CC1 and the 1-year
grade was CC2 / CC3.
• Baseline, 1996: 190 people.
Major TT 135. Minor TT 55.
• Follow-up, 1997: 169 people
were re-examined at 12
months
• Loss to follow-up: 21
• Incident CO in
individuals with TT: 10/104
(10%) / 1 year
• Progressive CO in
individuals with un-
operated Major TT: 33/96
(34%) / 1 year
• Hypoendemic setting (Regional survey
data)
• No previous MDA
• Clinical grading: detailed WHO-FPC system
used for cornea grading.[3]
• Change in vision over one year:
 8/88 (9%) had incident visual impairment or
blindness.
• There was a non-signiﬁcant trend to more
visual deterioration with major TT (9%)
compared to minor TT (4%) at baseline.
Gambia,
2006 [23]
Four year longitudinal study of individuals
with TT in at least one eye, who had
declined surgery. Examined at baseline and
4 years.
• Baseline, 1996: 220 people
• Follow-up, 2000: 153 people
were re-examined, with 241
eyes that had not been
surgically treated.
• Loss to follow-up: 67
• Incident CO in eyes with
TT at baseline: 16/211
(7.6%) / 4 years.
• Progression rate: 1.9%/
year
• Hypoendemic setting (Regional survey
data)
• No previous MDA
• Clinical grading: detailed WHO-FPC
system.[3]
• At baseline 30/241 eyes had CO.
• CO was only found in eyes with TT. New
CO was associated with the presence of
Major TT at 4-years (14/16 had major TT).
Incident CO by 4 years was more frequent in
eyes that had Major TT at baseline:
Minor or no TT at baseline: 6/117 (5.1%)
Major TT at baseline: 10/99 (10.1%).
• There was an overall deterioration in visual
acuity over the 4 years, of 0.22 LogMAR unit.
This change was more marked (non-
signiﬁcant) for eyes with TT (0.30) than for
those without TT (0.15). 29/221 eyes had
newly deteriorated to <3/60. However, only 6/
29 were due to CO, the large majority were
due to cataract.
(Continued)
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consistent with the observation that TS incidence is higher in females and with increasing age.
This model has since been incorporated into the design of mathematical models of the scarring
sequelae of trachoma [15, 16]. The second route, which may account for a minority of people
who develop TS, is characterised by the development of a severe and persistent inflammatory
phenotype, “constant severe trachoma”. Data from several of these prospective studies is con-
sistent with this hypothesis [10–12]. Whether these individuals are responding unfavourably to
C. trachomatis, to other bacteria, or are genetically prone to develop a severe persistent inflam-
matory phenotype is unclear [4].
Progression of Scarring Trachoma
We identified four prospective cohort studies which reported the rates and risk factors for the
progression of established trachomatous conjunctival scarring (Table 2) [10, 13, 17]. One was
from Tunisia, one from Ethiopia and two from Tanzania. There was some heterogeneity in the
study designs, although the two parallel studies we conducted in Ethiopia and Tanzania used
similar designs and were reported together [17]. Three studies were conducted in hyperen-
demic communities [10, 13, 17] and one in a hypoendemic community [17]. The Tunisian and
both Tanzanian studies were in areas which had not previously received MDA [10, 13, 17].
After enrolment, three of the study populations received some form of antibiotic treatment for
trachoma control, although this was variable in nature and frequency (Table 2). The Ethiopian
study was conducted in an area that had previously received MDA on several occasions and
continued to do so during the study period [17]. The second Tanzanian study was conducted
in an area where the current prevalence of active trachoma is below treatment thresholds [17].
The duration of follow-up varied from 2 to 14 years. The assessment of clinical signs used
either the simplified or detailed WHO Trachoma Grading Systems [2, 3].
The identification of progressive scarring used different methodologies. In the Tunisian
study the development of scarring was based on a change in the clinical field grading score
[10]. In the other three studies the progression of scarring was identified through the grading
of photographs. For one study this was done by the comparison of an independent grading of
the baseline and five-year photographs [11]. In the other two studies the baseline and two-year
photographs were graded using a detailed grading system for scarring [18]. The photographs
were directly compared side-by-side for assessment of progression, possibly allowing for more
subtle changes in TS to be detected [17].
The Tunisian study (described above) reported scarring progression in 68.5% of individuals
(n = 120) over 14 years (Table 2) [10]. However, this report is limited in the level of detail
Table 5. (Continued)
Country /
Year
Study design Participants Progression of TT to CO Comments
Ethiopia,
2011 [17]
Two year prospective randomised controlled
trial of epilation vs surgery for Minor
trichiasis (<6 lashes). 650 individuals were
randomised to the epilation arm at baseline
and followed every six months for two years.
The change in CO was assessed by direct
comparison on digital photographs.
• Baseline, 2008: 650 people
• Primary outcome data
available for 637 people.
• Loss to follow-up: 13
• Change in CO, in people
with Minor trichiasis who
were epilating at 2 years:
• Increased CO: 33/603
(5.5%) / 2 years; 2.75%/
year
• Reduced CO: 7/603
(1.2%) / 2 years; 0.6%/
year
• Hyperendemic setting (Regional survey
data)
• Clinical grading: detailed WHO-FPC
system, with more detailed grading of corneal
scarring on photographs.[3]
• MDA had been delivered in this region of
Ethiopia several times before the start of the
study and during the two year period.
• One eye per person analysed.
• 87/603 (14.5%) had a deterioration in visual
acuity of >0.3 LogMAR units by 2 years. Most
of this was not associated with a deterioration
in CO, suggesting that other causes such as
cataract were responsible.
doi:10.1371/journal.pntd.0004859.t005
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provided and it appears that the total progression estimate may include some individuals who
were incident scarring cases. There is some partial information on progression from mild or
moderate scarring (C1 / C2) to the most severe grade (C3), Table 2. The specific risk factors for
progression to C3 are not presented. However, as noted above, the development of new C3 in
those who had no scarring at baseline was associated with TI at baseline.
In the first Tanzanian study progression of conjunctival scarring occurred in 47.1% of indi-
viduals (n = 85, all ages) who had some established TS at baseline, over a five year period
(Table 2) [13]. There was no difference by age in the proportion with evidence of progression.
No data on the relationship between scarring progression and gender, clinical inflammation or
C. trachomatis infection were reported.
In our study in Ethiopia, progression of conjunctival scarring developed in 23.1% of partici-
pants (n = 585) over a 2 year period (Table 2) [17]. This was a prospective cohort of adults who
had minor trichiasis at baseline that was managed by epilation. They were examined and pho-
tographed every six months, with swab samples collected for C. trachomatis PCR and conjunc-
tival gene expression analysis. There was a strong relationship between progressive scarring
and increasing number of observed episodes of clinical inflammation, defined as P2 or P3 in
the detailed WHO grading system (OR 5.93, 95%CI 3.3–10.6, p<0.0001). There was no evi-
dence of an association between scarring progression and gender, age or body mass index
(BMI). The samples from individuals with progressive scarring and a frequency matched sam-
ple of individuals who did not show progressive scarring were tested for C. trachomatis by PCR
on 4 occasions; all samples were negative for C. trachomatis. Conjunctival inflammation, but
not scarring progression, was associated with increased gene expression of a mixture of pro-
inflammatory cytokines (IL1B, IL17A, CXCL5), anti-microbial effectors (S100A7) and factors
associated with tissue remodelling (CTGF,MMP7, reduced SPARCL1).
In the parallel cohort study we conducted in Tanzania we used the same protocol, including
sample collection, as the Ethiopian study; all individuals had conjunctival scarring at baseline,
were aged 18 years or more and no individuals had baseline trichiasis [17]. Progression of con-
junctival scarring was observed in 30.0% of participants (n = 577) over a 2-year period
(Table 2). Again, there was a strong relationship between progressive scarring and an increas-
ing number of episodes of clinical inflammation (P2/P3), of a similar magnitude to that found
in the Ethiopian study (OR 5.76, 95% CI 2.6–12.7, p<0.0001). There was no evidence of an
association between scarring progression and gender, age or BMI. In this Tanzanian cohort
there were 804 people with TS recruited and tested for C. trachomatis by PCR at baseline, of
which only 4 samples were positive. At 6, 12 and 18 months after baseline, the samples from
the individuals with progressive scarring and a frequency matched sample of individuals in the
cohort who did not show progressive scarring were also tested for C. trachomatis and only one
sample was positive. In this study progressive scarring was associated with a modest increase in
expression of IL1B and S100A7. In addition, increased S100A7, IL17A, CXCL5,MMP7 and
CEACAM5 expression were associated with clinical inflammation (P2/P3).
A consistent finding across these studies was that trachomatous conjunctival scarring con-
tinues to progress over time. The studies are probably too heterogeneous to provide an overall
estimate range for disease progression. However, it is noticeable that in the two studies using
the same protocol the rates of scarring progression were similar [17]. Moreover, it might have
been anticipated that the Ethiopian cohort, which was conducted in a hyperendemic region,
would have experienced a greater proportion of progression than that observed in a region of
Tanzania that had a low level of active trachoma, and was therefore not included in the
national antibiotic distribution programme.
There was a strong association between conjunctival inflammation and progressive scarring,
with individuals experiencing more inflammatory episodes being at greater risk of progression
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[10, 17]. In two studies the immunofibrogenic correlates of clinically apparent inflammation
were investigated using gene expression analysis, and this demonstrated that its presence was
associated with increased expression of a range of pro-inflammatory factors [17]. These obser-
vations are consistent with the findings for incident scarring outlined above; children who
experienced more episodes of active trachomatous inflammation were more likely to develop
incident scarring (Table 1) [11, 12].
There are three noteworthy findings from these four cohort studies of progressive scarring.
Firstly, we found no published evidence that the progression of established scarring was associ-
ated with the detection of C. trachomatis infection [17]. Indeed, infection was detected in only
very few individuals with TS. This contrasts with the observation, albeit from limited prospec-
tive data, of an association between the development of incident scarring and episodes of chla-
mydial infection [12]. Secondly, we found no published evidence of a difference between males
and females in the proportions showing signs of scarring progression. Again, this contrasts
with the findings for incident scarring outlined above, which developed more frequently in
females (Table 1). Thirdly, amongst people with established scarring the proportion showing
scarring progression did not vary with age. This also contrasts with the findings for incident
scarring, which developed more frequently with increasing age.
Therefore, once TS is established the risk of scarring progression does not appear to be asso-
ciated with exactly the same set of risk factors that were associated with the development of
incident scarring. This could be interpreted as suggesting that progression of established scar-
ring is less dependent than incident scarring on recurrent C. trachomatis infection, episodes of
which are more frequent in females and accrue with increasing age. It may also indicate that
other factors such as non-chlamydial bacterial infection, a dry ocular surface or altered tissue
inflammatory or scarring responses may also contribute to a pro-inflammatory / pro-fibrotic
state. This might be anticipated as scarred ocular surface tissue probably has altered physiology
and compromised defence mechanisms. However, prospective data on these factors has not
been reported.
Progression to Trachomatous Trichiasis
We identified four prospective cohort studies which report rates and risk factors for the devel-
opment of trachomatous trichiasis (Table 3) [10, 19–21]. One was from Tunisia, one from Tan-
zania and two from The Gambia. In addition, we identified a mathematical model based on
cross-sectional data from Tanzania [14]. Two studies were conducted in hyperendemic areas
and two in hypoendemic areas. None of the study populations had previously received system-
atic MDA for trachoma control. After enrolment, two of the study populations received some
form of antibiotic treatment for trachoma control, although this was variable in nature and fre-
quency (Table 3) [10, 21]. The duration of follow-up varied from 5 to 14 years.
The Tunisian study (described above) reported incident TT in 8.0% over a 14 year period
[10]. The risk of developing TT was related to the baseline conjunctival scarring severity, being
1.2% in people with no scarring and rising to 38.1% in those with severe baseline scarring (C3),
Table 3. The Tanzanian study was a 7 year cohort of females with and without TS at baseline
[19]. In those with TS at baseline 9.2% developed TT, and of those without TS at baseline 0.6%
developed TT by 7-years. The development of TT was associated with increasing age and the
detection of C. trachomatis infection at the 7-year time-point. The number of individuals with
C. trachomatis infection at follow up was 60/513 (11.7%) in the group with TS at baseline and
36/501 (7.5%) in the group with no TS at baseline. The first of the Gambian studies reported
the 12-year incidence of TT in people with TS at baseline to be 6.4% [20]. The development of
TT was associated with increasing age. The second Gambian study was a five year study of all
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the residents of 14 villages, most (94%) of whom did not have scarring at baseline. The five
year cumulative incidence of TT in those>15 years was 0.4% [21].
The mathematical model estimated the 5 year cumulative incidence of TT in women from a
hyperendemic region of Tanzania using age-stratified cross sectional data from different clini-
cal stages [14]. The cumulative incidence of TT was highest in older women (6.4% versus 0.3%
in young women) and in women with TS at baseline (15.1% in 55–59 year olds, 3.2% in 15–19
year olds).
Progression of Trachomatous Trichiasis
We identified three prospective cohort studies that reported the rates and risk factors for the
progression of trachomatous trichiasis from unilateral to bilateral disease, or from minor tri-
chiasis (<6 lashes touching the eye) to major trichiasis (6+ lashes touching the eye), Table 4
[22–25]. Two of these were from The Gambia and one from Ethiopia. The Gambian studies
were both conducted in hypoendemic areas. The Ethiopian study was in a hyperendemic set-
ting with on-going MDA. The duration of follow-up varied from 1 to 4 years.
In the first Gambian study, 46% of people with unilateral trichiasis (n = 46) had developed
bilateral disease in one year [22]. Of those with minor trichiasis (n = 55), 33% progressed to
major trichiasis. In the second Gambian study 29% of people with unilateral trichiasis (n = 42)
progressed to bilateral disease in four years and 37% of minor trichiasis (n = 75) progressed to
major trichiasis [23]. In this second study several factors were analysed in relation to the pro-
gression of trichiasis over four years: age, gender, conjunctival inflammation (at four years),
chlamydial infection and pathological bacterial infection (at four years). In univariate analysis
only conjunctival inflammation at 4-years was associated with TT progression. However, no
factor was significant in a multivariable model. It is noteworthy that at 4-years both conjuncti-
val inflammation and bacterial infection were independently associated with the presence of
major trichiasis. Only 2/146 samples tested were positive for C. trachomatis at the 4-year time-
point.
The Ethiopian study was of a group of people with minor trichiasis (n = 650) who were in
the epilation arm of a randomised controlled trial of epilation vs. surgery, with regular follow
up over a two year period [24]. Individuals were equipped with high quality forceps and a rela-
tive was trained in how to perform epilation. During the first two years 13% of study eyes pro-
gressed from minor to major trichiasis. After two years all participants were offered surgery for
their trichiasis. About a third accepted surgery at two years, while the majority (n = 383) chose
to continue with epilation and were followed up for an additional two years [25]. Comparing
the amount of trichiasis by counting the absolute number of lashes touching the eye at baseline
with that at four years, 21.4% of these 383 individuals were found to have had some degree of
increase in the number of lashes touching the eye, however this was difficult to assess in the
context of regular epilation. In addition, 36.6% had only a modest increase in the degree of
entropion, although it should be noted that this is a variable and difficult clinical sign to grade.
In a multivariable model, over the four years, progression to major trichiasis was associated
with older age and having3 lashes touching the eye at baseline.
Progression to Corneal Opacification, Visual Impairment and Blindness
We identified four prospective cohort studies that reported the rates and risk factors for the
development of corneal opacification (CO) and visual impairment (Table 5) [20, 22–25]. Three
were from The Gambia, conducted in hypoendemic areas. One study was from a hyperendemic
area of Ethiopia, with on-going MDA. The duration of follow-up varied from 1 to 12 years. In
addition, the mathematical model based on Tanzanian cross-sectional data provided 10 year
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estimates for the development of CO [14]. We have not included prospective data on CO
change from clinical trials where TT was treated with surgery.
The first Gambian study found the 12-year cumulative progression from TS to CO to be
5.9% and for TT to CO to be 20% [20]. Risk factors for incident CO were increasing age and
TT at baseline. Visual impairment developed in 16.5%, but only 2.5% of this was attributed to
CO; most was due to cataract (Table 5). The second Gambian study found that in one year inci-
dent CO developed in 10% of people with TT and that CO progressed in 34% with major tri-
chiasis [22]. New visual impairment or blindness developed in 9%. The third study from The
Gambia found incident CO developed in 7.6% of eyes with TT at baseline over the course of
four years, with the risk being greater for those with major TT (Table 5) [23]. Again, the risk of
visual impairment was increased with TT, however, the large majority of incident cases of
visual impairment were due to cataract.
The four year Ethiopian study of people with minor trichiasis has been outlined above [24,
25]. Incident or progressive CO was determined by the comparison of photographs in this
study. At 2 years, 5.5% of the 650 individuals with minor trichiasis had some increase in CO.
When modelled at 4-years, incident/progressive CO was associated with being50 years of
age and having moderate CO at baseline. Visual acuity deteriorated in 14.5% by>0.3LogMAR
by 2 years, however, most of this was not attributable to changes in CO.
The mathematical modelling study, described above, found that the overall incidence of CO
was higher in older women: 2.8% in 45–54 years versus 0.16% in 15–24 years [14]. The cumula-
tive incidence rates were estimated to be very much higher in those with TT at baseline: 53.5%
in 45–54 year olds and 27.2% in 15–24 year olds. This model estimated around half of all CO
was due to causes other than trachoma. In women<35 years these other causes dominated,
whereas in older women trachoma was the main cause.
Conclusions
Conducting long-term prospective studies of the rates and risk factors of progressive trachoma
from active disease through to blindness is complex and expensive. Here we have reviewed the
longitudinal studies that contribute to our understanding of this disease process. In addition to
these longitudinal studies, there are many cross-sectional studies that provide indirect evidence
about risk factors for progression. The prospective studies are relatively few in number, of vari-
able design and frequently small in size. The determination of the presence of progression in
conjunctival scarring can be challenging, particularly where there is also extensive inflamma-
tion masking scar tissue. Despite these limitations, collectively they provide evidence that sup-
ports much of the widely accepted description of the natural history of trachoma, illustrated in
Fig 1.
The studies of incident and progressive conjunctival scarring were consistent in showing a
strong association with repeated or persistent conjunctival inflammation. In contrast, the evi-
dence linking the development of incident conjunctival scarring with C. trachomatis infection
is limited to only one study. Moreover, in two large cohorts with scarring progression rates of
23.1% and 30% over 2 years only very few episodes of chlamydial infection were detected.
The model proposed by West and colleagues, and outlined above, suggests that the majority
of individuals who develop TS do so after repeated rounds of infection by C. trachomatis. In
addition, there appears to be a subgroup of individuals who experience repeated or protracted
intense inflammation, who are at increased risk of developing scarring. It is anticipated that the
introduction of control programmes involving MDA and F and E interventions to limit trans-
mission, will reduce the number of episodes of infection experienced and therefore the risk of
developing incident scarring. However, the potential impact of control measures on halting
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progression of previously established scarring is less certain. A treatment intervention that
could reduce chronic conjunctival inflammation in adults in trachoma-endemic areas might be
desirable to prevent scarring progression.
The lack of a clear association between chlamydial infection and scarring progression in
adults could have a number of explanations [17]. It is possible that the number and frequency
of clinical observations and tests for chlamydial infection in these studies were too few to cap-
ture infection events. It is also possible that the detection of infection in adults is more difficult
than in children, because of lower infection loads or shorter infection duration, due to the
acquisition of some protective immunity [26–28]. This potential explanation might imply that
only brief bursts of infection with C. trachomatis is needed to trigger chronic inflammation
and an associated scarring response.
Alternatively, it is possible that conjunctival inflammation observed in adults with estab-
lished conjunctival scarring may have additional causes besides C. trachomatis. A number of
studies have found cross-sectional associations between non-chlamydial bacteria cultured from
the conjunctival surface and the presence of inflammation at all stages of the natural history of
trachoma [23, 29–33]. Currently however there are no longitudinal data to determine whether
this inflammation associated with other infections represents a pro-fibrotic state that contrib-
utes additional scarring, or whether it is a by-product of the altered physiological environment
of a scarred conjunctiva. Longitudinal studies that include tests for C. trachomatis and non-
chlamydial bacteria are needed to determine their relative contributions to scarring
progression.
These observations raise important issues of programmatic significance for trachoma con-
trol, particularly over whether conjunctival scarring can continue to develop and progress in
individuals with intermittent or chronic inflammation, but in the absence of on-going regular
chlamydial infection. Several long-term population based studies of the impact of MDA have
demonstrated that even after C. trachomatis has been cleared or brought down to very low
prevalence levels, the prevalence of signs of active conjunctival inflammation persist for some
years [21, 34]. While it is possible that the cross-sectional nature of these studies may have
missed recent infection episodes, it is striking that the inflammatory phenotype was still pres-
ent after the prevalence of C. trachomatis infection had been reduced to a low level, and this
may have significance for disease progression. A question worth consideration is whether the
clinical sign TI should be included in the monitoring of trachoma control in addition to TF,
because of the consistently strong association between TI and incident and progressive scar-
ring. Finally, these data support the recommendation that trachoma control programmes
maintain mechanisms to detect and treat trichiasis for many years to come.
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